This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Cardiovascular System  • Congestive Heart Failure/ Cardiomyopathy  • Alert me on articles by topic  Social Bookmarking   What's this?

Sergio L. Pinski, MD

JAMA. 2003;289:754-756.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Despite advances in its medical management, severe congestive heart failure remains associated with substantial morbidity and mortality. Prognosis has improved only slightly during the past decade among unselected community patients with congestive heart failure.¹ It appears that the benefits documented in large randomized clinical trials have not been fully realized. Two articles in this issue of THE JOURNAL describe encouraging findings regarding 2 relatively novel therapeutic approaches for congestive heart failure: -blockers and cardiac resynchronization therapy.

During the last 5 years, randomized clinical trials have consistently demonstrated that several -blocking agents (bisoprolol, carvedilol, and metoprolol) substantially reduce morbidity and mortality in a wide spectrum of patients with heart failure and depressed left ventricular systolic function.² Thus, current practice guidelines recommend -blockers as first-line therapy in all patients with symptomatic left ventricular systolic dysfunction.³ -Blocker utilization, however, is not yet widespread, especially among primary care physicians. A . . . [Full Text of this Article]

Author Affiliation: Department of Cardiology, Cleveland Clinic Florida, Weston.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Effects of Initiating Carvedilol in Patients With Severe Chronic Heart Failure: Results From the COPERNICUS Study
Henry Krum, Ellen B. Roecker, Paul Mohacsi, Jean L. Rouleau, Michal Tendera, Andrew J. S. Coats, Hugo A. Katus, Michael B. Fowler, Milton Packer, and for the Carvedilol Prospective Randomized Cumulative Survival Study Group
JAMA. 2003;289(6):712-718.
ABSTRACT | FULL TEXT  

Cardiac Resynchronization and Death From Progressive Heart Failure: A Meta-analysis of Randomized Controlled Trials
David J. Bradley, Elizabeth A. Bradley, Kenneth L. Baughman, Ronald D. Berger, Hugh Calkins, Steven N. Goodman, David A. Kass, and Neil R. Powe
JAMA. 2003;289(6):730-740.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cardiogenic shock shortly after initial success of cardiac resynchronization therapy
Kanhai et al.
Eur J Heart Fail 2004;6:477-481.
ABSTRACT | FULL TEXT  

Beta-Blockade for Severe Heart Failure: Early Effects
Journal Watch Cardiology 2003;2003:3-3.
FULL TEXT  

Cardiac Resynchronization Therapy Limits Mortality Due to Progressive Heart Failure
Journal Watch Cardiology 2003;2003:2-2.
FULL TEXT